S
Hoji Alimi
Founder, President, and CEO, Oculus Innovative Sciences
SECRET TO HIS SUCCESS: Conviction
FAVE MOVIE: Gladiator—"It shows the importance of the greater good"
Hoji Alimi, whose father was a general in the Iranian army, was exiled as a teen when the Shah was desposed. "Life wasn't handed to me on a silver platter," he says. He became a microbiologist, honing his skills at AVE (bought by Medtronic) as a biologist and toxicologist. While pursuing his master's degree, he found a promising cancer compound—but his professor refused the data, which contradicted other findings. Alimi used it to found Micromet Labs.
Hoji Alimi
"My wife and I wanted to buy a house," he says. "I told her, we could buy it and that would be our life—or we could take this opportunity. She said to go for it or I'd regret it for the rest of my life."
Another compound soon caught Alimi's attention. An investor sent him a liquid shown to induce rapid wound healing. "For four years, I worked by day at Micromet and then would stay up trying to reformulate the product to be stable. People asked when I was going to give up."
But Alimi didn't give up, and has since shown Microcyn, as trademarked, to be more effective than levofloxicin at helping burn patients leave the hospital, and is effective against drug-resistant bacteria. Now this wound care solution is marketed around the world—and just completed Phase II trials in the US.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.